CYBN 250117 22.50P (CYBN250117P22500) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Jan 17 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Stock_Drift

Jan 15 11:27

$Cybin (CYBN.US)$

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Trytosaveabit

Jan 15 11:09

Update

$Cybin (CYBN.US)$ Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
1 MINUTE AGO, 12:07 PM EST
VIA BUSINESSWIRE
Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance -
- First program member is Segal Trials, a preferred pr...

Jaguar8

Jan 15 11:07

NEWS

$Cybin (CYBN.US)$
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Wednesday, 15th January at 12:07 pm
- Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance -
- First program member is Segal Trials, a preferred provider fo...

Jaguar8

Jan 13 06:33

NEWS

$Cybin (CYBN.US)$
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Monday, 13th January at 7:30 am
- Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder ("MDD") -
- Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of MDD –
- Received U.S. Food and Drug Administration ("FDA") Breakthrough Therapy Designation ("BTD") for CYB003 for the Adjunc...

Jaguar8

Dec 10, 2024 06:44

NEWS

$Cybin (CYBN.US)$
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Tuesday, 10th December at 7:30 am
- Poster presentations highlight clinical data across Cybin's CYB003 deuterated psilocin and DMT programs -
Cybin Inc. (NYSE: CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new...